We evaluated the sandwich enzyme-linked immunosorbent assay (ELISA) MARKIT 1 -M for the determination of heart fatty-acid-binding protein (H-FABP).
Introduction
Heart fatty acid-binding protein (H-FABP) is a protein of relatively small size (13^15 kDa) that is present in the cytoplasm of cardiac myocytes at higher concentrations (4^8% of total cytoplasmic protein) than in skeletal muscle cells (51% of total cytoplasmic protein). 1 Because of its small size, relative hearttissue speci¢city and abundance in heart muscle, H-FABP has been suggested as a potential indicator of ischaemic myocardial damage. 2 We have evaluated a commercial enzyme -linked immunosorbent assay (ELISA) for H-FABP (MARKIT 1 -M; Dainippon Pharmaceutical Co., Osaka, Japan).
Materials and methods
In the MARKIT-M assay, standard H-FABP (puri¢ed from human heart muscle) or patients' samples were prediluted with potassium phosphate bu¡er and placed in a well coated with an anti-human H-FABP monoclonal antibody (mAb 8E3). After incubation and washing, a second anti-human H-FABP mAb (8B9) labelled with horseradish peroxidase was added, incubated and the absorbance measured at 492/620 nm after addition of substrate.
The method was compared with an established sandwich ELISA that uses recombinant human H-FABP as standard. 3 This latter assay had a detection limit of 2¢0 mg/ L and an analytical range of 0^250 mg/L.
The serum concentration of myoglobin was measured immunometrically with an Opus analyser (Dade Behring, Deer¢eld IL, USA).
Serum samples (nˆ75), randomly selected from patients with chest pain, were analysed on the same day by both H-FABP methods. Samples were also obtained from 30 apparently healthy subjects (12 women and 18 men, aged 39^60 years), as well as from 41 consecutive patients with chest pain, within 5 h [mean 2¢6 h, standard deviation (SD) 1¢2 h] of onset of symptoms. Myocardial infarction (MI) was diagnosed in 34 of these patients.
Results and discussion
The detection limit, de¢ned as 3 SD above the mean absorbance (nˆ20) of the zero calibrator, was1¢5 mg/L. The intra-assay coe¤cient of variation (CV) was 2¢2^3¢7 (nˆ20) and the between-run CV was 3¢4^3¢9 (nˆ10). This was well within the suggested analytical goal of 47%. 4 High concentrations of haemoglobin 
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(4 g/L) and triglycerides (10¢2 mmol/ L) did not interfere with the assay. There was good correlation between the MARKIT-M assay and the established ELISA method (rˆ0¢970). There was a mean bias of 1¢1 mg/L [95% con¢dence interval (CI): 70 ¢2 to 2¢4 mg/L]. Considering the di¡erent mAbs and calibration materials used in the two assays, the agreement was good.
The upper reference limit (97¢5th centile) in healthy subjects was 6¢1 mg/L. Thus the detection limit of the assay was su¤ciently low to permit the determination of H-FABP concentrations in serum samples from healthy individuals. The reference interval for myoglobin was 14^49 mg/L.
The values found for H-FABP in healthy individuals were di¡erent from those previously reported using a di¡erent commercial assay. 5 Di¡erences in calibration materials or in the speci¢city of the mAbs could explain this discrepancy.
H-FABP showed the same diagnostic e¤ciency as myoglobin [area (standard error) under the receiver operating characteristic (ROC) curve: 0¢798 (0¢079) for H-FABP, 0¢771 (0¢085) for myoglobin, Pˆ0 ¢55] (see Fig. 1 ). The sensitivity and speci¢city of H-FABP for the early detection of MI using the best discriminant value (16¢0 mg/L) were 59% (CI: 41^75%) and 86% (CI: 42^98%), respectively. Corresponding values for myoglobin (discriminant value, 52 mg/L) were 65% (CI: 47^80%) and 100% (CI: 59^100%), respectively. The clinical sensitivity of H-FABP versus myoglobin was also evaluated using the upper reference limit as the decision cut-o¡. In this case, the result for H-FABP (91%; CI: 76^98%) was signi¢cantly (Pˆ0¢019) higher than that for myoglobin (65%; CI: 47^80%).
Conclusion
Although the present ¢ndings do not permit ¢rm conclusions because of the small population of patients studied, H-FABP has the potential to exclude MI signi¢cantly earlier than the existing markers do. De¢nitive evaluation and clinical application of H-FABP as an early marker of MI will, however, require a rapid assay procedure. 
